| Company Name: |
TargetMol Chemicals Inc.
|
| Tel: |
15002134094 |
| Email: |
marketing@targetmol.cn |
| Products Intro: |
Product Name:UBX-382
CAS:2884554-45-2
Package:10mg;50mg
|
|
| | UBX-382 Basic information |
| Product Name: | UBX-382 | | Synonyms: | UBX-382;1H-Isoindole-1,3(2H)-dione, 5-[4-[[7-[[3-[(2,6-dimethylphenyl)amino]-1-methyl-1H-pyrazolo[3,4-d]pyrimidin-6-yl]amino]-3,4-dihydro-2(1H)-isoquinolinyl]methyl]-1-piperidinyl]-2-(2,6-dioxo-3-piperidinyl)- | | CAS: | 2884554-45-2 | | MF: | C42H44N10O4 | | MW: | 752.88 | | EINECS: | | | Product Categories: | | | Mol File: | 2884554-45-2.mol |  |
| | UBX-382 Chemical Properties |
| density | 1.48±0.1 g/cm3(Predicted) | | form | Solid | | pka | 10.83±0.40(Predicted) | | color | Light yellow to green yellow |
| | UBX-382 Usage And Synthesis |
| Uses | UBX-382 is an orally available proteolysis-targeting chimeras (PROTACs) that target BTK to inactivate B-cell receptor signaling. UBX-382 shows superior degradation activity for wild-type and mutant BTK proteins and shows anti-cancer activity in murine xenograft models of TMD-8 cells[1]. | | References | [1] Lim YS, et al. Orally bioavailable BTK PROTAC active against wild-type and C481 mutant BTKs in human lymphoma CDX mouse models. Blood Adv. 2023;7(1):92-105. DOI:10.1182/bloodadvances.2022008121 |
| | UBX-382 Preparation Products And Raw materials |
|